Cargando…
Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine
Earlier research primarily attributed the effects of mesenchymal stem cell (MSC) therapies to their capacity for local engrafting and differentiating into multiple tissue types. However, recent studies have revealed that implanted cells do not survive for long, and that the benefits of MSC therapy c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618501/ https://www.ncbi.nlm.nih.gov/pubmed/28841158 http://dx.doi.org/10.3390/ijms18091852 |
_version_ | 1783267200766836736 |
---|---|
author | Vizoso, Francisco J. Eiro, Noemi Cid, Sandra Schneider, Jose Perez-Fernandez, Roman |
author_facet | Vizoso, Francisco J. Eiro, Noemi Cid, Sandra Schneider, Jose Perez-Fernandez, Roman |
author_sort | Vizoso, Francisco J. |
collection | PubMed |
description | Earlier research primarily attributed the effects of mesenchymal stem cell (MSC) therapies to their capacity for local engrafting and differentiating into multiple tissue types. However, recent studies have revealed that implanted cells do not survive for long, and that the benefits of MSC therapy could be due to the vast array of bioactive factors they produce, which play an important role in the regulation of key biologic processes. Secretome derivatives, such as conditioned media or exosomes, may present considerable advantages over cells for manufacturing, storage, handling, product shelf life and their potential as a ready-to-go biologic product. Nevertheless, regulatory requirements for manufacturing and quality control will be necessary to establish the safety and efficacy profile of these products. Among MSCs, human uterine cervical stem cells (hUCESCs) may be a good candidate for obtaining secretome-derived products. hUCESCs are obtained by Pap cervical smear, which is a less invasive and painful method than those used for obtaining other MSCs (for example, from bone marrow or adipose tissue). Moreover, due to easy isolation and a high proliferative rate, it is possible to obtain large amounts of hUCESCs or secretome-derived products for research and clinical use. |
format | Online Article Text |
id | pubmed-5618501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56185012017-09-30 Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine Vizoso, Francisco J. Eiro, Noemi Cid, Sandra Schneider, Jose Perez-Fernandez, Roman Int J Mol Sci Review Earlier research primarily attributed the effects of mesenchymal stem cell (MSC) therapies to their capacity for local engrafting and differentiating into multiple tissue types. However, recent studies have revealed that implanted cells do not survive for long, and that the benefits of MSC therapy could be due to the vast array of bioactive factors they produce, which play an important role in the regulation of key biologic processes. Secretome derivatives, such as conditioned media or exosomes, may present considerable advantages over cells for manufacturing, storage, handling, product shelf life and their potential as a ready-to-go biologic product. Nevertheless, regulatory requirements for manufacturing and quality control will be necessary to establish the safety and efficacy profile of these products. Among MSCs, human uterine cervical stem cells (hUCESCs) may be a good candidate for obtaining secretome-derived products. hUCESCs are obtained by Pap cervical smear, which is a less invasive and painful method than those used for obtaining other MSCs (for example, from bone marrow or adipose tissue). Moreover, due to easy isolation and a high proliferative rate, it is possible to obtain large amounts of hUCESCs or secretome-derived products for research and clinical use. MDPI 2017-08-25 /pmc/articles/PMC5618501/ /pubmed/28841158 http://dx.doi.org/10.3390/ijms18091852 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vizoso, Francisco J. Eiro, Noemi Cid, Sandra Schneider, Jose Perez-Fernandez, Roman Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine |
title | Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine |
title_full | Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine |
title_fullStr | Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine |
title_full_unstemmed | Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine |
title_short | Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine |
title_sort | mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618501/ https://www.ncbi.nlm.nih.gov/pubmed/28841158 http://dx.doi.org/10.3390/ijms18091852 |
work_keys_str_mv | AT vizosofranciscoj mesenchymalstemcellsecretometowardcellfreetherapeuticstrategiesinregenerativemedicine AT eironoemi mesenchymalstemcellsecretometowardcellfreetherapeuticstrategiesinregenerativemedicine AT cidsandra mesenchymalstemcellsecretometowardcellfreetherapeuticstrategiesinregenerativemedicine AT schneiderjose mesenchymalstemcellsecretometowardcellfreetherapeuticstrategiesinregenerativemedicine AT perezfernandezroman mesenchymalstemcellsecretometowardcellfreetherapeuticstrategiesinregenerativemedicine |